Maxidex

Dexamethasone, the active ingredient in Maxidex, is a corticosteroid presented as an ophthalmic preparation for ocular use. It treats postoperative ocular inflammation, uveitis, allergic conjunctivitis and other inflammatory eye conditions. GNH USA supplies Maxidex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxidex, a corticosteroid eye drop, is used to manage inflammatory conditions of the eye. - Post‑operative ocular inflammation: reduces swelling and pain after eye surgery. - Uveitis: controls intra‑ocular inflammation and prevents tissue damage. - Allergic conjunctivitis: alleviates redness, itching and swelling caused by allergens. - Other inflammatory eye conditions: provides anti‑inflammatory relief in various ocular disorders.

Adverse reactions may occur with ocular dexamethasone use.

Common Side Effects: - Eye irritation or burning sensation. - Transient blurred vision. - Increased intra‑ocular pressure. - Mild cataract formation with prolonged use. - Dry eye sensation.

Serious or Rare Side Effects: - Secondary ocular infection. - Glaucoma development. - Delayed wound healing after surgery. - Severe allergic reaction (e.g., angioedema). - Retinal detachment. - Persistent corneal ulceration.

Before using Maxidex, consider the following safety measures. - Monitor intra‑ocular pressure: regular eye pressure checks are recommended. - Avoid use in active viral eye infections: may worsen the condition. - Use with caution in diabetic patients: steroids can affect glucose control. - Do not combine with other corticosteroid eye drops unless directed by a clinician. - Store at room temperature: keep in the original container, protect from light and moisture.

Dexamethasone eye drops can interact with certain medications.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Antiviral eye agents (e.g., ganciclovir): may reduce antiviral efficacy. - Non‑steroidal anti‑inflammatory eye drops: increased risk of corneal thinning.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: possible alteration of intra‑ocular pressure control. - Anticholinergic eye preparations: may affect tear production. - Cyclosporine eye drops: potential additive immunosuppression.